At Orion, we turn raw materials into respiratory medicine.
As a provider of pharmaceutical products, we carry the main responsibility of the uncompromised quality and safety of our products and related services, and we ensure the quality and sustainability of our extensive supply chain.
As a full-scale pharmaceutical company, we focus on the whole value chain. We have broad experience in pharmaceutical manufacturing and comprehensive supply chain operations.
Our proprietary Easyhaler® dry powder formulations as well as our multidose dry powder inhaler products are manufactured in our own production plant in Espoo, Finland. The facilities feature, for instance, a state-of-the-art cleanroom and new filling and packaging lines, as well as efficient component flow for inhalation production.
All our own manufacturing plants are located in Finland. Our compliant manufacturing facilities are approved by regulatory authorities.
For generic drugs, we select only the best certified active pharmaceutical ingredients (API) manufacturers on the global market. The pharmaceutical ingredients, device platform and packaging materials are produced by dozens of suppliers in different countries.
With our subsidiary Fermion, we can develop and manufacture high-quality APIs. See more here.
Sustainability is integrated into our entire product lifecycle management: from chemicals and raw materials manufacturing and resourcing, to product manufacturing and packaging.
We believe that responsible supply starts from sourcing. Risk management is a key theme in our evaluation of supplier markets. When we screen potential suppliers during the selection phase of our process, we conduct on-site audits or require supplier self-assessments, focusing more extensively on ethical business operations.
We also engage in supplier relationship management. To support the achievement of common goals, we provide supplier training sessions as necessary through the Pharmaceutical Supply Chain Initiative (PSCI), which promotes sustainable practices in the pharmaceutical industry.
Orion is constantly seeking and evaluating potential new partnerships. We have the capability to reliably manufacture respiratory products in high volumes. The main focus indications are asthma and chronic obstructive pulmonary disease (COPD).
